Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Anpassa FAMS för att optimera användningen av CGM bland nya vuxna med typ 1-diabetes

30 oktober 2026 uppdaterad av: Lindsay Mayberry, Vanderbilt University Medical Center

The goal of this clinical trial is to evaluate the efficacy of an adapted FAMS (Family/friend Activation to Motivate Self-care) intervention on CGM use among study participants who are CGM users. We will leverage the infrastructure of an NIDDK-funded RCT evaluating FAMS-T1D among N=280 emerging adults with T1D who have elevated hemoglobin A1c or elevated diabetes distress (NCT05820477). We anticipate at least 50% using CGM to be included in these analyses.

Studieöversikt

Status

Aktiv, inte rekryterande

Betingelser

Detaljerad beskrivning

FAMS (Family/friend Activation to Motivate Self-care) is a mobile phone-delivered intervention, based on Family Systems Theory, which helps adults with diabetes set behavioral goals and improve support received from friends and family for goal success. FAMS includes monthly phone coaching and text message support by FAMS coaches for the person with diabetes (PWD) and the option to enroll a support person (SP) to receive automated texts tailored to the self-care goals the person with T1D sets in coaching sessions. Adaptations specific to CGM include the option to set CGM use goals in coaching (and receive associated text support) and skill-building exercises during coaching to support data sharing relationships (e.g., establishing, setting and adjusting ground rules about communication).

Within the FAMS-T1D RCT (NCT05820477), we will test effects of FAMS-T1D on CGM use use relative to enhanced treatment as usual. We will evaluate effects on CGM use from baseline to post-intervention (6 months) as the primary endpoint. Study start date for the nested trial (NCT05854069) is the enrollment date of the first participant using a CGM. Since the goal of this trial is to assess effects of the adapted FAMS intervention on CGM use, the date participant CGM usage was confirmed is considered the enrollment date.

Studietyp

Interventionell

Inskrivning (Beräknad)

140

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • California
      • Los Angeles, California, Förenta staterna, 90027
        • Children's Hospital of Los Angeles
    • Utah
      • Salt Lake City, Utah, Förenta staterna, 84112
        • University of Utah

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 24 år (Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

PERSONS WITH DIABETES

  • Ages 18-24
  • Have a diagnosis of T1D and has been taking insulin for at least one year
  • Comfortable sending and receiving texts
  • Can speak, read, and write in English
  • Meets one of the following two criteria: 1) has a most recent A1c value in the EHR that is 7.5% or higher (or missing) OR 2) screen positive for diabetes distress on the two-item Diabetes Distress Screen (DDS-2)
  • Using a continuous glucose monitor (CGM)

SUPPORT PERSONS

  • Age 18 or older
  • Can speak, read, and write in English or Spanish
  • Comfortable sending and receiving texts

Exclusion Criteria:

PERSONS WITH DIABETES

  • Has a condition that would prohibit study completion (intellectual disability, blindness or auditory limitations, severe mental illness)
  • Plans to live outside the country during the study period

SUPPORT PERSONS

  • Shares a phone with the person with diabetes
  • Plans to live outside of the country during the study period

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Stödjande vård
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: FAMS-T1D

Participants will receive FAMS-T1D components (monthly phone coaching and text message support for goals) for 6 months. Support persons will receive text messages that are tailored to the goal set by the person with type 1 diabetes.

All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.

FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled.

Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly.

Andra namn:
  • Familj/vänaktivering för att motivera egenvård för personer med typ 1-diabetes

Quality digital resources about diabetes management provided upon enrollment and during the study.

Placebo-jämförare: Digital resources for diabetes

All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.

Quality digital resources about diabetes management provided upon enrollment and during the study.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
CGM frequency of use during the intervention period
Tidsram: Baseline and 6 months post-baseline

Change in CGM frequency of use assessed by self-report on questionnaire; more frequent use/higher is better

Baseline and 6 months post-baseline
CGM frequency of use during the intervention period
Tidsram: Baseline and 6 months post-baseline

Change in CGM frequency of use assessed by objective CGM data (% of time; higher is better)

Baseline and 6 months post-baseline
Gaps in CGM use
Tidsram: 6 months post-baseline

Length of gaps in CGM use as assessed by objective CGM data (measured in number of consecutive days without CGM data; higher is worse)

6 months post-baseline

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
CGM behavioral responses during the intervention period
Tidsram: Baseline and 6 months post-baseline

Change in frequency of making behavioral changes in response to CGM data assessed by self-report; higher scores indicate more frequent response (better)

Baseline and 6 months post-baseline
Barriers to CGM use during the intervention period
Tidsram: Baseline and 6 months post-baseline

Change in perceived influence of CGM on glycemic control scale assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)

Baseline and 6 months post-baseline
Barriers to CGM use during the intervention period
Tidsram: Baseline and 6 months post-baseline

Change in perceived influence of CGM on social complications assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)

Baseline and 6 months post-baseline
CGM satisfaction during the intervention period
Tidsram: Baseline and 6 months post-baseline

Change in CGM satisfaction assessed by Benefits of CGM scale; higher scores indicate more perceived benefits of CGM use (better)

Baseline and 6 months post-baseline

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Data sharing during the intervention period
Tidsram: 6 months post-baseline

Number of data sharing relationships, between groups; more is better

6 months post-baseline
Satisfaction with data-sharing relationships
Tidsram: 6 months post-baseline

Satisfaction with data-sharing relationships assessed by CGM-Satisfaction Scale; higher scores are better

6 months post-baseline

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

30 april 2023

Primärt slutförande (Beräknad)

31 januari 2027

Avslutad studie (Beräknad)

30 april 2027

Studieregistreringsdatum

Först inskickad

24 april 2023

Först inskickad som uppfyllde QC-kriterierna

9 maj 2023

Första postat (Faktisk)

11 maj 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

3 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

30 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

After study results are posted on clinical trials and published, de-identified data will be available upon requests made to the principal investigator.

Tidsram för IPD-delning

After study results are posted on clinical trials and outcomes published in a peer-reviewed journal, until 5 years later.

Kriterier för IPD Sharing Access

Contact the principal investigator

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ICF

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera